Bellicum brings in some CAR-T assets; Sangamo heralds Phase II success with HIV therapy;

@FierceBiotech: AstraZeneca bets on the future of the 'secretome,' joining a $100M research effort. Story | Follow @FierceBiotech

@JohnCFierce: If @woodfordfunds didn't know about the questions circulating around $NWBO, you have to wonder if the DC vax thing came up for review. | Follow @JohnCFierce

@DamianFierce: A lot of culturally embarrassing quotes in this, but reporters calling 5% "an obscure black movement" is as damning as anything Shkreli says. | Follow @DamianFierce

> Bellicum Pharmaceuticals ($BLCM) signed a deal with Astellas for the rights to cancer-fighting cell therapies that dovetail with its work in CAR-T treatments. More

> Sanofi ($SNY) is reportedly close to hiring a Morgan Stanley banker to sit at the head of its M&A operation. News

> Sangamo Biosciences ($SGMO) said its HIV therapy succeeded in a pair of Phase II trials. Release

Medical Device News

@FierceMedDev: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. More | Follow @FierceMedDev

@EmilyWFierce: Novian Health reveals positive study results for breast cancer laser ablation device. Article | Follow @EmilyWFierce

> Medtronic, Samsung partner to develop neuromodulation implant apps for smart devices. Story

> Lab experts lash out at FDA move to beef up regulation of lab-developed tests. News

Pharma News

@FiercePharma: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. More | Follow @FiercePharma

@EricPFierce: #Sun #Pharma to launch generic Gleevec Feb. 1 but has said it won't be #manufacturing it at troubled Halol plant. Story | Follow @EricPFierce

@CarlyHFierce: Horizon shells out $510 million for access to gout med Kyrstexxa. News | Follow @CarlyHFierce

> Discount sways U.K. cost gatekeeper on AstraZeneca's ovarian cancer med Lynparza. More

> Sanofi's and Regeneron's Praluent wins top billing on UnitedHealth Group's formulary. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.